Breaking Finance News

Credit Suisse announced Ascendis Pharma A S (NASDAQ:ASND), boosting its stock price target to $28.00 today

In a report issued Thursday February 09, 2017 Credit Suisse increased the stock price target of Ascendis Pharma A S (NASDAQ:ASND) to $28.00 stating a potential upside of 0.21%.

On 1/31/2017, Zacks Investment Research released a statement about Ascendis Pharma A S (NASDAQ:ASND) upped the target price from $0.00 to $24.00 that suggested an upside of 0.12%.

Having a price of $23.05, Ascendis Pharma A S (NASDAQ:ASND) traded 2.61% higher on the day. With the last stock price up 21.07% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.06% over the same period. ASND has recorded a 50-day average of $21.12 and a two hundred day average of $19.46. Trade Volume was up over the average, with 52,969 shares of ASND changing hands over the typical 48,021

Recent Performance Chart

Ascendis Pharma A S (NASDAQ:ASND)

Ascendis Pharma A S has with a one year low of $11.92 and a one year high of $24.20 and has a market capitalization of $0.

General Company Details For Ascendis Pharma A S (NASDAQ:ASND)

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma and Endocrinology Division A/S (Denmark).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.